Table of Content

1. Market Background

1.1 Scope and Product Outlook

1.2 Executive Summary

1.3 Research Methodology



2. Strategic Recommendations



3. Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Historic and Forecast (2020-2030)

3.1 Impact Analysis of Macro Economic Factors on Glucagon-Like Peptide 1 (GLP-1) Agonist Market

3.2 Pipeline Analysis of GLP-1 Agonist Market

3.3 Global Obesity Statistics 2022, in Millions

3.4 Diabetes Statistics

3.5 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Dashboard

3.6 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Value Assessment, 2020-2030 (USD Million)

3.7 Impact of COVID-19 on Glucagon-Like Peptide 1 (GLP-1) Agonist Market

3.8 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Type

3.8.1 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Type Overview

3.8.2 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Tirzepatide, By Value, 2020H-2030F (USD Million & CAGR)

3.8.3 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Semaglutide, By Value, 2020H-2030F (USD Million & CAGR)

3.8.4 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Dulaglutide, By Value, 2020H-2030F (USD Million & CAGR)

3.8.5 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Other Types, By Value, 2020H-2030F (USD Million & CAGR)

3.9 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Distribution Channel

3.9.1 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel Overview

3.9.2 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Clinics, By Value, 2020H-2030F (USD Million & CAGR)

3.9.3 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Ambulatory Surgical Centers, By Value, 2020H-2030F (USD Million & CAGR)

3.9.4 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)

3.10 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Route of Administration

3.10.1 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration Overview

3.10.2 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Oral, By Value, 2020H-2030F (USD Million & CAGR)

3.10.3 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)

3.11 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By End-Use

3.11.1 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use Overview

3.11.2 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Type 2 Diabetes, By Value, 2020H-2030F (USD Million & CAGR)

3.11.3 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By NASH, By Value, 2020H-2030F (USD Million & CAGR)

3.11.4 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Obesity, By Value, 2020H-2030F (USD Million & CAGR)



4. Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Regional Analysis

4.1 Regional Coverage of the Study

4.2 Regional Snapshot



5. Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Historic and Forecast (2020-2030)

5.1 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Snapshot

5.2 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Value Assessment, 2020-2030 (USD Million & CAGR)

5.3 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Key Factors

5.4 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Value Assessment

5.5 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Dynamics

5.6 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Distribution Channel

5.6.1 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel Overview

5.6.2 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Clinics, By Value, 2020H-2030F (USD Million & CAGR)

5.6.3 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Ambulatory Surgical Centers, By Value, 2020H-2030F (USD Million & CAGR)

5.6.4 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)

5.7 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Route of Administration

5.7.1 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration Overview

5.7.2 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Oral, By Value, 2020H-2030F (USD Million & CAGR)

5.7.3 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)

5.8 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By End-Use

5.8.1 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use Overview

5.8.2 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Type 2 Diabetes, By Value, 2020H-2030F (USD Million & CAGR)

5.8.3 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By NASH, By Value, 2020H-2030F (USD Million & CAGR)

5.8.4 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Obesity, By Value, 2020H-2030F (USD Million & CAGR)

5.9 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Country

5.9.1 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Country Overview

5.9.2 United States Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)

5.9.2.1 United States Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel

5.9.2.2 United States Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration

5.9.2.3 United States Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use

5.9.3 Canada Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)

5.9.3.1 Canada Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use

5.9.3.2 Canada Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration

5.9.3.3 Canada Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel

5.9.4 Rest of Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)

5.9.4.1 Rest of Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use

5.9.4.2 Rest of Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration

5.9.4.3 Rest of Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel


6. Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Historic and Forecast (2020-2030)

6.1 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Snapshot

6.2 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Value Assessment, 2020-2030 (USD Million & CAGR)

6.3 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Key Factors

6.4 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Value Assessment

6.5 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Dynamics

6.6 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Distribution Channel

6.6.1 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel Overview

6.6.2 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Clinics, By Value, 2020H-2030F (USD Million & CAGR)

6.6.3 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Ambulatory Surgical Centers, By Value, 2020H-2030F (USD Million & CAGR)

6.6.4 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)

6.7 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Route of Administration

6.7.1 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration Overview

6.7.2 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Oral, By Value, 2020H-2030F (USD Million & CAGR)

6.7.3 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)

6.8 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By End-Use

6.8.1 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use Overview

6.8.3 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Type 2 Diabetes, By Value, 2020H-2030F (USD Million & CAGR)

6.8.4 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By NASH, By Value, 2020H-2030F (USD Million & CAGR)

6.8.5 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Obesity, By Value, 2020H-2030F (USD Million & CAGR)

6.9 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Country

6.9.1 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Country Overview

6.9.2 United Kingdom Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)

6.9.2.1 United Kingdom Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel

6.9.2.2 United Kingdom Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration

6.9.2.3 United Kingdom Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use

6.9.3 Germany Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)

6.9.3.1 Germany Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel

6.9.3.2 Germany Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration

6.9.3.3 Germany Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use

6.9.4 France Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)

6.9.4.1 France Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel

6.9.4.2 France Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration

6.9.4.3 France Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use

6.9.5 Italy Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)

6.9.5.1 Italy Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel

6.9.5.2 Italy Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration

6.9.5.3 Italy Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use

6.9.6 Rest of Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)

6.9.6.1 Rest of Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel

6.9.6.2 Rest of Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration

6.9.6.3 Rest of Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use



7. Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Historic and Forecast (2020-2030)

7.1 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Snapshot

7.2 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Value Assessment, 2020-2030 (USD Million & CAGR)

7.3 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Key Factors

7.4 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Value Assessment

7.5 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Dynamics

7.6 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Distribution Channel

7.6.1 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel Overview

7.6.2 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Clinics, By Value, 2020H-2030F (USD Million & CAGR)

7.6.3 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Ambulatory Surgical Centers, By Value, 2020H-2030F (USD Million & CAGR)

7.6.4 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)

7.7 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Route of Administration

7.7.1 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration Overview

7.7.2 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Oral, By Value, 2020H-2030F (USD Million & CAGR)

7.7.3 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)

7.8 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By End-Use

7.8.1 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use Overview

7.8.2 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Type 2 Diabetes, By Value, 2020H-2030F (USD Million & CAGR)

7.8.3 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By NASH, By Value, 2020H-2030F (USD Million & CAGR)

7.8.4 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Obesity, By Value, 2020H-2030F (USD Million & CAGR)

7.9 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Country

7.9.1 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Country Overview

7.9.2 China Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)

7.9.2.1 China Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel

7.9.2.2 China Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration

7.9.2.3 China Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use

7.9.3 Japan Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)

7.9.3.1 Japan Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel

7.9.3.2 Japan Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration

7.9.3.3 Japan Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use

7.9.4 South Korea Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)

7.9.4.1 South Korea Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel

7.9.4.2 South Korea Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration

7.9.4.3 South Korea Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use

7.9.5 India Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)

7.9.5.1 India Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel

7.9.5.2 India Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration

7.9.5.3 India Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use

7.9.6 Rest of Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)

7.9.6.1 Rest of Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel

7.9.6.2 Rest of Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration

7.9.6.3 Rest of Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use


8. Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Historic and Forecast (2020-2030)

8.1 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Snapshot

8.2 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Value Assessment, 2020-2030 (USD Million & CAGR)

8.3 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Key Factors

8.4 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Value Assessment

8.5 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Dynamics

8.6 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Distribution Channel

8.6.1 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel Overview

8.6.2 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Clinics, By Value, 2020H-2030F (USD Million & CAGR)

8.6.3 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Ambulatory Surgical Centers, By Value, 2020H-2030F (USD Million & CAGR)

8.6.4 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)

8.7 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Route of Administration

8.7.1 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration Overview

8.7.2 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Oral, By Value, 2020H-2030F (USD Million & CAGR)

8.7.3 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)

8.8 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By End-Use

8.8.1 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use Overview

8.8.2 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Type 2 Diabetes, By Value, 2020H-2030F (USD Million & CAGR)

8.8.3 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By NASH, By Value, 2020H-2030F (USD Million & CAGR)

8.8.4 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Obesity, By Value, 2020H-2030F (USD Million & CAGR)



9. Market Dynamics

9.1 Impact Assessment of Market Dynamics on Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market

9.2 Drivers

9.3 Restraints

9.4 Trends



10. Industry Ecosystem Analysis

10.1 Porter’s Five Forces Model



11. Competitive Positioning

11.1 Companies’ Product Positioning

11.2 Market Share Analysis of Glucagon-Like Peptide 1 (GLP-1) Agonist Market

11.3 Company Profiles

11.3.1 Eli Lilly and Company

11.3.2 Pfizer

11.3.3 Sanofi

11.3.4 AstraZeneca PLC

11.3.5 Boehringer Ingelheim

11.3.6 Novo Nordisk



List of Figures

List of Figures

Figure 1: Global Obesity Statistics 2022 (In Millions)

Figure 2: People with diabetes in Thousands, (20-79 y)

Figure 3: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Value, 2020-2022 (USD Million)

Figure 4: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Value, 2023-2030 (USD Million)

Figure 5: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market CAGR (%), By Value, 2020-2023, 2024-2030

Figure 6: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Tirzepatide, By Value, 2020H-2030F (USD Million & CAGR)

Figure 7: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Absolute Opportunity, By Tirzepatide, 2020-2030 (USD Million)

Figure 8: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Semaglutide, By Value, 2020H-2030F (USD Million & CAGR)

Figure 9: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Absolute Opportunity, By Semaglutide, 2020-2030 (USD Million)

Figure 10: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Dulaglutide, By Value, 2020H-2030F (USD Million & CAGR)

Figure 11: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Absolute Opportunity, By Dulaglutide, 2020-2030 (USD Million)

Figure 12: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Other Types, By Value, 2020H-2030F (USD Million & CAGR)

Figure 13: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Absolute Opportunity, By Other Types, 2020-2030 (USD Million)

Figure 14: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Clinics, By Value, 2020H-2030F (USD Million & CAGR)

Figure 15: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Absolute Opportunity, By Clinics, 2020-2030 (USD Million)

Figure 16: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Ambulatory Surgical Centers, By Value, 2020H-2030F (USD Million & CAGR)

Figure 17: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Absolute Opportunity, By Ambulatory Surgical Centers, 2020-2030 (USD Million)

Figure 18: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)

Figure 19: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Absolute Opportunity, By Hospitals, 2020-2030 (USD Million)

Figure 20: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Oral, By Value, 2020H-2030F (USD Million & CAGR)

Figure 21: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Absolute Opportunity, By Oral, 2020-2030 (USD Million)

Figure 22: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)

Figure 23: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Absolute Opportunity, By Parenteral, 2020-2030 (USD Million)

Figure 24: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Type 2 Diabetes, By Value, 2020H-2030F (USD Million & CAGR)

Figure 25: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Absolute Opportunity, By Type 2 Diabetes, 2020-2030 (USD Million)

Figure 26: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By NASH, By Value, 2020H-2030F (USD Million & CAGR)

Figure 27: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Absolute Opportunity, By NASH, 2020-2030 (USD Million)

Figure 28: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Obesity, By Value, 2020H-2030F (USD Million & CAGR)

Figure 29: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Absolute Opportunity, By Obesity, 2020-2030 (USD Million)

Figure 30: Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Value, 2020H-2030F (USD Million)

Figure 31: Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By End-Use, 2022 (%)

Figure 32: Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Clinics, By Value, 2020H-2030F (USD Million & CAGR)

Figure 33: Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Ambulatory Surgical Centers, By Value, 2020H-2030F (USD Million & CAGR)

Figure 34: Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)

Figure 35: Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Oral, By Value, 2020H-2030F (USD Million & CAGR)

Figure 36: Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)

Figure 37: Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Type 2 Diabetes, By Value, 2020H-2030F (USD Million & CAGR)

Figure 38: Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By NASH, By Value, 2020H-2030F (USD Million & CAGR)

Figure 39: Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Obesity, By Value, 2020H-2030F (USD Million & CAGR)

Figure 40: United States Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Value, 2020-2030 (USD Million & CAGR)

Figure 41: United States Glucagon-Like Peptide 1 (GLP-1) Agonist Market Value, By End-Use, 2022 (USD Million)

Figure 42: United States Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Distribution Channel, 2022 (%)

Figure 43: United States Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Route of Administration, By Value, 2022 (%)

Figure 44: United States Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By End-Use, 2022 (%)

Figure 45: Canada Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Value, 2020-2030 (USD Million & CAGR)

Figure 46: Canada Glucagon-Like Peptide 1 (GLP-1) Agonist Market Value, By End-Use, 2022 (USD Million)

Figure 47: Canada Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Distribution Channel, 2022 (%)

Figure 48: Canada Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Route of Administration, By Value, 2022 (%)

Figure 49: Canada Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By End-Use, 2022 (%)

Figure 50: Rest of Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Value, 2020-2030 (USD Million & CAGR)

Figure 51: Rest of Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Value, By End-Use, 2022 (USD Million)

Figure 52: Rest of Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Distribution Channel, 2022 (%)

Figure 53: Rest of Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Route of Administration, By Value, 2022 (%)

Figure 54: Rest of Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By End-Use, 2022 (%)

Figure 55: Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Value, 2020H-2030F (USD Million)

Figure 56: Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By End-Use, 2022 (%)

Figure 57: Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Clinics, By Value, 2020H-2030F (USD Million & CAGR)

Figure 58: Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Ambulatory Surgical Centers, By Value, 2020H-2030F (USD Million & CAGR)

Figure 59: Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)

Figure 60: Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Oral, By Value, 2020H-2030F (USD Million & CAGR)

Figure 61: Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)

Figure 62: Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Type 2 Diabetes, By Value, 2020H-2030F (USD Million & CAGR)

Figure 63: Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By NASH, By Value, 2020H-2030F (USD Million & CAGR)

Figure 64: Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Obesity, By Value, 2020H-2030F (USD Million & CAGR)

Figure 65: United Kingdom Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Value, 2020-2030 (USD Million & CAGR)

Figure 66: United Kingdom Glucagon-Like Peptide 1 (GLP-1) Agonist Market Value, By End-Use, 2022 (USD Million)

Figure 67: United Kingdom Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Distribution Channel, 2022 (%)

Figure 68: United Kingdom Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Route of Administration, By Value, 2022 (%)

Figure 69: United Kingdom Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By End-Use, 2022 (%)

Figure 70: Germany Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Value, 2020-2030 (USD Million & CAGR)

Figure 71: Germany Glucagon-Like Peptide 1 (GLP-1) Agonist Market Value, By End-Use, 2022 (USD Million)

Figure 72: Germany Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Distribution Channel, 2022 (%)

Figure 73: Germany Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Route of Administration, By Value, 2022 (%)

Figure 74: Germany Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By End-Use, 2022 (%)

Figure 75: France Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Value, 2020-2030 (USD Million & CAGR)

Figure 76: France Glucagon-Like Peptide 1 (GLP-1) Agonist Market Value, By End-Use, 2022 (USD Million)

Figure 77: France Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Distribution Channel, 2022 (%)

Figure 78: France Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Route of Administration, By Value, 2022 (%)

Figure 79: France Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By End-Use, 2022 (%)

Figure 80: Italy Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Value, 2020-2030 (USD Million & CAGR)

Figure 81: Italy Glucagon-Like Peptide 1 (GLP-1) Agonist Market Value, By End-Use, 2022 (USD Million)

Figure 82: Italy Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Distribution Channel, 2022 (%)

Figure 83: Italy Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Route of Administration, By Value, 2022 (%)

Figure 84: Italy Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By End-Use, 2022 (%)

Figure 85: Rest of Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Value, 2020-2030 (USD Million & CAGR)

Figure 86: Rest of Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Value, By End-Use, 2022 (USD Million)

Figure 87: Rest of Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Distribution Channel, 2022 (%)

Figure 88: Rest of Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Route of Administration, By Value, 2022 (%)

Figure 89: Rest of Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By End-Use, 2022 (%)

Figure 90: Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Value, 2020H-2030F (USD Million)

Figure 91: Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By End-Use, 2022 (%)

Figure 92: Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Clinics, By Value, 2020H-2030F (USD Million & CAGR)

Figure 93: Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Ambulatory Surgical Centers, By Value, 2020H-2030F (USD Million & CAGR)

Figure 94: Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)

Figure 95: Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Oral, By Value, 2020H-2030F (USD Million & CAGR)

Figure 96: Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)

Figure 97: Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Type 2 Diabetes, By Value, 2020H-2030F (USD Million & CAGR)

Figure 98: Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By NASH, By Value, 2020H-2030F (USD Million & CAGR)

Figure 99: Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Obesity, By Value, 2020H-2030F (USD Million & CAGR)

Figure 100: China Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Value, 2020-2030 (USD Million & CAGR)

Figure 101: China Glucagon-Like Peptide 1 (GLP-1) Agonist Market Value, By End-Use, 2022 (USD Million)

Figure 102: China Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Distribution Channel, 2022 (%)

Figure 103: China Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Route of Administration, By Value, 2022 (%)

Figure 104: China Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By End-Use, 2022 (%)

Figure 105: Japan Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Value, 2020-2030 (USD Million & CAGR)

Figure 106: Japan Glucagon-Like Peptide 1 (GLP-1) Agonist Market Value, By End-Use, 2022 (USD Million)

Figure 107: Japan Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Distribution Channel, 2022 (%)

Figure 108: Japan Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Route of Administration, 2022 (%)

Figure 109: Japan Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By End-Use, By Value, 2022 (%)

Figure 110: South Korea Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Value, 2020-2030 (USD Million & CAGR)

Figure 111: South Korea Glucagon-Like Peptide 1 (GLP-1) Agonist Market Value, By End-Use, 2022 (USD Million)

Figure 112: South Korea Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Distribution Channel, 2022 (%)

Figure 113: South Korea Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Route of Administration, 2022 (%)

Figure 114: South Korea Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By End-Use, By Value, 2022 (%)

Figure 115: India Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Value, 2020-2030 (USD Million & CAGR)

Figure 116: India Glucagon-Like Peptide 1 (GLP-1) Agonist Market Value, By End-Use, 2022 (USD Million)

Figure 117: India Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Distribution Channel, 2022 (%)

Figure 118: India Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Route of Administration, 2022 (%)

Figure 119: India Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By End-Use, By Value, 2022 (%)

Figure 120: Rest of Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Value, 2020-2030 (USD Million & CAGR)

Figure 121: Rest of Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Value, By End-Use, 2022 (USD Million)

Figure 122: Rest of Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Distribution Channel, 2022 (%)

Figure 123: Rest of Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Route of Administration, 2022 (%)

Figure 124: Rest of Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By End-Use, By Value, 2022 (%)

Figure 125: Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Value, 2020H-2030F (USD Million)

Figure 126: Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By End-Use, 2022 (%)

Figure 127: Middle East and Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Clinics, By Value, 2020H-2030F (USD Million & CAGR)

Figure 128: Middle East and Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Ambulatory Surgical Centers, By Value, 2020H-2030F (USD Million & CAGR)

Figure 129: Middle East and Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)

Figure 130: Middle East and Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Oral, By Value, 2020H-2030F (USD Million & CAGR)

Figure 131: Middle East and Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)

Figure 132: Middle East and Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Type 2 Diabetes, By Value, 2020H-2030F (USD Million & CAGR)

Figure 133: Middle East and Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By NASH, By Value, 2020H-2030F (USD Million & CAGR)

Figure 134: Middle East and Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Obesity, By Value, 2020H-2030F (USD Million & CAGR)

Figure 135: Market Share of Prominent Companies of Glucagon-Like Peptide 1 (GLP-1) Agonist Market, 2022 (%)

Figure 136: Eli Lilly and Company Revenues, 2020-2022 (USD Million)

Figure 137: Eli Lilly and Company Revenues, By Geographic Segments, 2022 (%)

Figure 138: Eli Lilly and Company Revenue, By Therapeutic Area, 2022 (%)

Figure 139: Pfizer Revenues, 2020-2022 (USD Million)

Figure 140: Pfizer Revenues, By Business Segments, 2022 (%)

Figure 141: Pfizer Inc. Revenue, By Geographical Segments, 2022 (%)

Figure 142: Sanofi Revenues, 2020-2022 (USD Million)

Figure 143: Sanofi Revenues, By Geographic Segments, 2022 (%)

Figure 144: Sanofi Revenue, By Business Segments, 2022 (%)

Figure 145: AstraZeneca PLC Revenues, 2020-2022 (USD Million)

Figure 146: AstraZeneca PLC Revenues, By Geographic Segments, 2022 (%)

Figure 147: AstraZeneca PLC Revenue, By Business Segments, 2022 (%)

Figure 148: Novo Nordisk Revenues, 2020-2022 (USD Million)

Figure 149: Novo Nordisk Revenues, By Geographic Segments, 2022 (%)

Figure 150: Novo Nordisk Revenue, By Therapeutic Area, 2022 (%)


List of Tables

Table A1: Global Impact of Macro Economic Factors, By Region

Table A2: Details of GLP-1 Agonist in several stages of clinical trials

Table A3: United States Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2020-2023 (USD Million)

Table A4: United States Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2024-2030 (USD Million)

Table A5: United States Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2020-2023 (USD Million)

Table A6: United States Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2024-2030 (USD Million)

Table A7: United States Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2020-2023 (USD Million)

Table A8: United States Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2024-2030 (USD Million)

Table A9: Canada Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2020-2023 (USD Million)

Table A10: Canada Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2024-2030 (USD Million)

Table A11: Canada Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2020-2023 (USD Million)

Table A12: Canada Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2024-2030 (USD Million)

Table A13: Canada Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2020-2023 (USD Million)

Table A14: Canada Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2024-2030 (USD Million)

Table A15: Rest of Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2020-2023 (USD Million)

Table A16: Rest of Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2024-2030 (USD Million)

Table A17: Rest of Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2020-2023 (USD Million)

Table A18: Rest of Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2024-2030 (USD Million)

Table A19: Rest of Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2020-2023 (USD Million)

Table A20: Rest of Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2024-2030 (USD Million)

Table A21: United Kingdom Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2020-2023 (USD Million)

Table A22: United Kingdom Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2024-2030 (USD Million)

Table A23: United Kingdom Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2020-2023 (USD Million)

Table A24: United Kingdom Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2024-2030 (USD Million)

Table A25: United Kingdom Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2020-2023 (USD Million)

Table A26: United Kingdom Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2024-2030 (USD Million)

Table A27: Germany Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2020-2023 (USD Million)

Table A28: Germany Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2024-2030 (USD Million)

Table A29: Germany Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2020-2023 (USD Million)

Table A30: Germany Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2024-2030 (USD Million)

Table A31: Germany Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2020-2023 (USD Million)

Table A32: Germany Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2024-2030 (USD Million)

Table A33: France Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2020-2023 (USD Million)

Table A34: France Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2024-2030 (USD Million)

Table A35: France Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2020-2023 (USD Million)

Table A36: France Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2024-2030 (USD Million)

Table A37: France Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2020-2023 (USD Million)

Table A38: France Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2024-2030 (USD Million)

Table A39: Italy Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2020-2023 (USD Million)

Table A40: Italy Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2024-2030 (USD Million)

Table A41: Italy Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2020-2023 (USD Million)

Table A42: Italy Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2024-2030 (USD Million)

Table A43: Italy Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2020-2023 (USD Million)

Table A44: Italy Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2024-2030 (USD Million)

Table A45: Rest of Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2020-2023 (USD Million)

Table A46: Rest of Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2024-2030 (USD Million)

Table A47: Rest of Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2020-2023 (USD Million)

Table A48: Rest of Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2024-2030 (USD Million)

Table A49: Rest of Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2020-2023 (USD Million)

Table A50: Rest of Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2024-2030 (USD Million)

Table A51: China Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2020-2023 (USD Million)

Table A52: China Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2024-2030 (USD Million)

Table A53: China Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2020-2023 (USD Million)

Table A54: China Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2024-2030 (USD Million)

Table A55: China Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2020-2023 (USD Million)

Table A56: China Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2024-2030 (USD Million)

Table A57: Japan Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2020-2023 (USD Million)

Table A58: Japan Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2024-2030 (USD Million)

Table A59: Japan Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2020-2023 (USD Million)

Table A60: Japan Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2024-2030 (USD Million)

Table A61: Japan Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2020-2023 (USD Million)

Table A62: Japan Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2024-2030 (USD Million)

Table A63: South Korea Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2020-2023 (USD Million)

Table A64: South Korea Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2024-2030 (USD Million)

Table A65: South Korea Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2020-2023 (USD Million)

Table A66: South Korea Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2024-2030 (USD Million)

Table A67: South Korea Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2020-2023 (USD Million)

Table A68: South Korea Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2024-2030 (USD Million)

Table A69: India Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2020-2023 (USD Million)

Table A70: India Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2024-2030 (USD Million)

Table A71: India Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2020-2023 (USD Million)

Table A72: India Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2024-2030 (USD Million)

Table A73: India Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2020-2023 (USD Million)

Table A74: India Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2024-2030 (USD Million)

Table A75: Rest of Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2020-2023 (USD Million)

Table A76: Rest of Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2024-2030 (USD Million)

Table A77: Rest of Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2020-2023 (USD Million)

Table A78: Rest of Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2024-2030 (USD Million)

Table A79: Rest of Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2020-2023 (USD Million)

Table A80: Rest of Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2024-2030 (USD Million)

Table A81: Eli Lilly and Company Key Financials, 2020-2022

Table A82: Pfizer Key Financials, 2020-2022

Table A83: Sanofi Key Financials, 2020-2022

Table A84: AstraZeneca PLC Key Financials, 2020-2022

Table A85: Novo Nordisk Key Financials, 2020-2022